BR9803296A - Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma. - Google Patents

Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.

Info

Publication number
BR9803296A
BR9803296A BR9803296-8A BR9803296A BR9803296A BR 9803296 A BR9803296 A BR 9803296A BR 9803296 A BR9803296 A BR 9803296A BR 9803296 A BR9803296 A BR 9803296A
Authority
BR
Brazil
Prior art keywords
molecule
fas
antibody
treatment
prophylaxis
Prior art date
Application number
BR9803296-8A
Other languages
English (en)
Inventor
Nobufusa Serizawa
Kimihisa Ichikawa
Jun Ohsumi
Masahiko Ohtsuki
Hideyuki Haruyama
Tohru Takahashi
Hiroko Yoshida
Akio Shiraishi
Shin Yonehara
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR9803296A publication Critical patent/BR9803296A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"MOLéCULA, ANTICORPO, USO DE UMA MOLéCULA, DNA, VETOR DE DNA RECOMBINANTE, CéLULA HOSPEDEIRA, MICROORGANISMO, PROCESSO PARA PRODUZIR UM ANTICORPO, AGENTE PARA O TRATAMENTO OU PROFILAXIA DE CONDIçõES ATRIBUìVEIS A ANORMALIDADES DO SISTEMA LIGANDO FAS/FAS, USO DE UMA MOLéCULA E HIBRIDOMA". Anticorpos Fas anti-humanos que são reativos cruzados com Fas de camundongo e humano são utilizáveis no tratamento de condições atribuíveis a anormalidades no sistema ligando Fas/Fas.
BR9803296-8A 1997-04-01 1998-04-01 Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma. BR9803296A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8295397 1997-04-01
JP16908897 1997-06-25
JP27606497 1997-10-08

Publications (1)

Publication Number Publication Date
BR9803296A true BR9803296A (pt) 2000-01-11

Family

ID=27304060

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9803296-8A BR9803296A (pt) 1997-04-01 1998-04-01 Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.

Country Status (17)

Country Link
EP (1) EP0909816A1 (pt)
KR (1) KR19980080993A (pt)
CN (1) CN1207395A (pt)
AR (1) AR010139A1 (pt)
AU (1) AU734758B2 (pt)
BR (1) BR9803296A (pt)
CA (1) CA2233783A1 (pt)
CZ (1) CZ294340B6 (pt)
HU (1) HUP9800744A3 (pt)
ID (1) ID20117A (pt)
IL (1) IL123888A0 (pt)
NO (1) NO981454L (pt)
NZ (1) NZ330095A (pt)
PL (1) PL325667A1 (pt)
RU (1) RU2212412C2 (pt)
TR (1) TR199800604A2 (pt)
TW (1) TW526205B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
ATE357459T1 (de) * 1998-01-23 2007-04-15 Hoffmann La Roche Antikörper gegen mensliches il-12
EP1087993B1 (en) 1998-06-18 2008-04-02 Imed Ab Fas peptides and antibodies for modulating apoptosis
AU757961B2 (en) * 1998-09-30 2003-03-13 Sankyo Company Limited Anti-Fas antibodies
HUP0201333A3 (en) 1999-05-24 2004-11-29 Sankyo Company Ltd Chuo Ku Medicinal compositions containing anti-fas antibody
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US20070129291A1 (en) * 2001-08-01 2007-06-07 Genset S.A. Genobix agonists and antagonists for use in the treatment of metabolic disorders
JP2005509412A (ja) 2001-08-23 2005-04-14 アールエスアール リミテッド チロトロフィン（ｔｓｈ）受容体の抗原決定領域、その使用およびその抗体
ES2357225T3 (es) 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
HUE026132T2 (en) 2004-01-07 2016-05-30 Novartis Vaccines & Diagnostics Inc M-CSF-specific monoclonal antibody and its uses
CN102170905B (zh) * 2008-08-01 2016-08-03 阿克西斯股份有限公司 骨关节炎治疗剂及预防剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0723556A4 (en) * 1993-10-14 2003-03-19 Immunex Corp FAS ANTAGONISTS AND THEIR APPLICATIONS
DE69535719T2 (de) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. Fas-antigenbindender ligand
AU6091496A (en) * 1995-06-07 1996-12-30 Chiron Corporation Antibodies to fas antigen capable of inhibiting apoptosis
GB9523469D0 (en) * 1995-11-16 1996-01-17 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
TR199800604A3 (tr) 1999-10-21
AU5970198A (en) 1998-10-08
RU2212412C2 (ru) 2003-09-20
CN1207395A (zh) 1999-02-10
HUP9800744A3 (en) 2001-04-28
CZ98598A3 (cs) 1998-10-14
CZ294340B6 (cs) 2004-12-15
PL325667A1 (en) 1998-10-12
AU734758B2 (en) 2001-06-21
EP0909816A1 (en) 1999-04-21
NO981454D0 (no) 1998-03-31
HU9800744D0 (en) 1998-05-28
CA2233783A1 (en) 1998-10-01
IL123888A0 (en) 1998-10-30
HUP9800744A2 (hu) 1999-02-01
NZ330095A (en) 1998-12-23
KR19980080993A (ko) 1998-11-25
TW526205B (en) 2003-04-01
ID20117A (id) 1998-10-01
AR010139A1 (es) 2000-05-17
TR199800604A2 (xx) 1999-10-21
NO981454L (no) 1998-10-02

Similar Documents

Publication Publication Date Title
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
CL2009000575A1 (es) Anticuerpos aislados anti-interleuquina 12 (anti il-12) de mamiferos, secuencia de nucleotidos, vector, celula y metodo de produccion, composicion y dispositivo medico que contienen, util en el diagnostico y tratamiento de condicones relacionadas con il-12.
BR9803296A (pt) Moléculam anticorpo,uso de uma molécula, dna, vetor de dna recombinante, célula hospedeira,microorganismo, processo para produzir um anticorpo agente para o tratamento ou profilaxia de condições atribuìveis a normalidades do sistema ligando fas/fas, uso de uma molécula e hibridoma.
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
DE69227041D1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DE69534235D1 (de) Cytokin lerk-7
ATE312920T1 (de) Dna immunisierung gegen chlamydia infektion
BR9808153A (pt) Processo para melhorar a fotossìntese
CY1109437T1 (el) ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
KR950032279A (ko) 인체의 프로그램된 세포 사멸과 관련 있는 펩티드 및 이를 암호하는 디엔에이(dna)
BR0212756A (pt) Molécula de anticorpo tendo especificidade para kdr humano, variante da molécula de anticorpo, composto, sequência de dna, vetor, célula hospedeira, processo para a produção da molécula de anticorpo, composição terapêutica ou diagnóstica, e, uso da molécula de anticorpo
BRPI0504146A (pt) processo catalìtico seletivo regenerativo
BR9904475A (pt) Molécula tipo anticorpo anti-fas, humanizada, agente para a profilaxia e/ou tratamento de condições envolvendo uma anormalidade no sistema ligando fas/fas, uso de um anticorpo, dna, vetor de dna recombinante, célula hospedeira, processo para produzir um anticorpo anti-pas, cepa transformante de e.coli, e, polipeptìdeo.
BR9608481A (pt) Anticorpos quiméricos para administração de antìgenos a células selecionadas do sistema imunológico.
AR036189A1 (es) Anticuerpos de interleuquina-1beta
BR0013043A (pt) Proteìna isolada, anticorpo isolado, composição, método de regulação de reação imunológica em animais, método de tratamento de câncer em animais, molécula de ácido nucleico isolado, molécula de ácido nucleico recombinante, célula recombinante e vìrus recombinante
BR0015287A (pt) Moléculas recombinantes de fusão
DK0457804T3 (da) M-CSF-monoklonale antistoffer, som genkender en neutraliserende, konformational epitop
DE69841331D1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
DE69940692D1 (de) Verwendung von immunogenen immunsuppressiven und/oder angiogenen proteinen die inaktiviert sind, verfahren zur deren herstellung, und verwendungen als pharmazeutikum oder impfstoff
BR9101117A (pt) Produto que compreende um ou mais veiculos de material enzimatico e processo para distribuir um agente ativo a um sitio
ATE98130T1 (de) Kombination von angiotensin-converting-enzymehemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln.
DE69839582D1 (de) Neues polypeptid, dafür kodierende dna und deren verwendungen
Beletskij et al. A parametric analysis of relative equilibrium stability in a gravitational field.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.